Cue Biopharma initiated with bullish view at Jefferies, here's why
In: The Fly, 2024-03-13
serialPeriodical
Zugriff:
Jefferies analyst Maury Raycroft initiated coverage of Cue Biopharma with a Buy rating and $6 price target. The company's novel IL-2 platform aims to improve on first generation IL-2 safety [...]
Titel: |
Cue Biopharma initiated with bullish view at Jefferies, here's why
|
---|---|
Zeitschrift: | The Fly, 2024-03-13 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
Schlagwort: |
|
Sonstiges: |
|